Gedatolisib, Fulvestrant, and Palbociclib Triplet Under Investigation in HR+/HER2– Breast Cancer

The combination of gedatolisib and fulvestrant with or without palbociclib is under evaluation in the phase 3 VIKTORIA-1 trial for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor–positive/HER2-negative breast cancer who have previously progressed on first-line therapy.

Related Keywords

San Antonio ,Texas ,United States ,Orlando ,Florida ,Tampa ,Heather Han , ,Breast Oncology ,Moffitt Cancer Center ,Antonio Breast Cancer Symposium ,Gedatolisib ,Fulvestrant ,Palbociclib ,Hase 3 Viktoria 1 Trial Nct05501886 ,Pik3ca Mutated ,Hormone Receptor Hr Positive Her2 Negative Breast Cancer ,First Line Therapy Witha Cdk4 6 Inhibitor ,2023 Aacr Annual Meeting ,